Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Parrish Capital LLC

Parrish Capital LLC reduced its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 20.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 77,150 shares of the company’s stock after selling 20,003 shares during the period. Teva Pharmaceutical Industries makes up approximately 2.1% of Parrish Capital LLC’s investment portfolio, making the stock its 8th biggest position. Parrish Capital LLC’s holdings in Teva Pharmaceutical Industries were worth $2,614,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. California State Teachers Retirement System increased its stake in Teva Pharmaceutical Industries by 3,376.3% during the 2nd quarter. California State Teachers Retirement System now owns 43,270,486 shares of the company’s stock worth $1,466,004,000 after acquiring an additional 42,025,742 shares during the period. HB Wealth Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at $295,000. Compass Financial Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth $1,093,000. TD Waterhouse Canada Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 5.3% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 186,889 shares of the company’s stock worth $6,250,000 after purchasing an additional 9,340 shares in the last quarter. Finally, Concurrent Investment Advisors LLC increased its position in shares of Teva Pharmaceutical Industries by 25.0% in the second quarter. Concurrent Investment Advisors LLC now owns 11,370 shares of the company’s stock worth $385,000 after purchasing an additional 2,277 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Weiss Ratings raised Teva Pharmaceutical Industries from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, August 21st. Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research report on Tuesday, July 28th. Finally, UBS Group upped their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a report on Friday. Nine equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $42.89.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $36.36 on Monday. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88. Teva Pharmaceutical Industries Ltd. has a 52 week low of $18.21 and a 52 week high of $38.37. The stock has a market capitalization of $42.37 billion, a P/E ratio of 60.60, a price-to-earnings-growth ratio of 4.53 and a beta of 0.87. The stock has a fifty day moving average of $34.64 and a 200-day moving average of $33.28.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%.The business had revenue of $4.14 billion for the quarter. On average, sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.94 earnings per share for the current fiscal year.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: S&P Global Ratings upgraded Teva’s long-term issuer rating to BBB- from BB+ with a stable outlook. Combined with recent Fitch and Moody’s upgrades, Teva now has investment-grade ratings from all major agencies, potentially lowering borrowing costs and improving flexibility to invest in growth. S&P Global Ratings upgrades Teva
• Positive Sentiment: UBS raised its price target on TEVA to $48 from $42 and maintained a Buy rating, citing potential upside from the company’s improved financial profile and growth strategy.
• Positive Sentiment: Teva reported positive Phase IIa results for its anti-IL-15 therapy TEV ’408 in celiac disease. The treatment met the study goal of preventing gluten-induced intestinal damage and showed a favorable safety profile, strengthening the late-stage pipeline. TEV ’408 celiac disease study
• Neutral Sentiment: Teva agreed to act as stalking-horse bidder for substantially all BioXcel Therapeutics assets in a Chapter 11 auction, offering up to $125 million in cash plus assumed liabilities. The deal could expand Teva’s at-home treatment opportunity, but the final purchase price and assets acquired remain uncertain. Teva-backed BioXcel bid
• Neutral Sentiment: Teva is advancing a plan to exchange its ordinary shares for American Depositary Shares on the NYSE, which could simplify trading and broaden access for U.S. investors, although the immediate earnings impact is limited. Teva NYSE listing update
• Negative Sentiment: Reported insider activity has been heavily weighted toward selling, with no insider purchases and 14 sales over the past six months. This may temper investor enthusiasm, though insider sales can reflect compensation or portfolio decisions rather than deteriorating fundamentals.

Insider Activity at Teva Pharmaceutical Industries

In other news, EVP Eliyahu Kalif sold 106,563 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $34.10, for a total value of $3,633,798.30. Following the sale, the executive vice president directly owned 65,621 shares in the company, valued at approximately $2,237,676.10. This trade represents a 61.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.54% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.